Effect of the hiv-1 integrase inhibitor raltegravir or drug susceptibility, replication capacity and residual viremia in hiv-infected subjects.

Tesis doctoral de María José Buzón Gómez Raltegravir is the first in-class hiv-1 integrase inhibitor approved for the treatment of […]

, , ,